Literature DB >> 23311768

Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.

T D Filippatos1, C S Derdemezis, P V Voulgari, V Tsimihodimos, M S Elisaf, A D Tselepis, A A Drosos.   

Abstract

OBJECTIVES: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. The aim of the present study was the assessment of low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass distribution in patients with early RA (ERA, n = 30) compared with age- and sex-matched healthy subjects (n = 30), as well the effect of treatment for 12 months with the disease-modifying anti-rheumatic drugs (DMARDs) methotrexate and prednisone in this distribution.
METHOD: LDL and HDL subclass distribution was determined using a polyacrylamide gel-tube electrophoresis method.
RESULTS: ERA patients exhibited increased levels of inflammatory markers and high disease activity score. ERA patients had higher serum levels of total cholesterol (TC), LDL cholesterol (LDL-C), and triglycerides (TG) whereas their serum HDL cholesterol (HDL-C) levels were significantly lower compared with controls. ERA patients exhibited significantly higher plasma levels of small dense LDL-C (sdLDL-C), leading to a significantly decreased mean LDL diameter. ERA patients had significantly decreased small HDL particles (HDL-3) concentration whereas serum levels of large HDL particles (HDL-2) did not differ compared with controls. Treatment with DMARDs resulted in a significant decrease in inflammatory markers and disease activity, along with a significant increase in HDL-C serum levels. The concentration of sdLDL-C did not change significantly during treatment. We observed a significant increase in the levels of large HDL-2 whereas the concentration of small HDL-3 did not significantly change.
CONCLUSIONS: Patients with ERA have increased sdLDL-C levels and decreased HDL-C levels because of decreased concentration of the small HDL-3 subclass. The administration of DMARDs induced a significant increase in HDL-C levels, which was attributed to the increase in large HDL-2 serum concentration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23311768     DOI: 10.3109/03009742.2012.745013

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  9 in total

1.  Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Authors:  Theodosios D Filippatos; Evangelos C Rizos; Vasilios Tsimihodimos; Irene F Gazi; Alexandros D Tselepis; Moses S Elisaf
Journal:  Lipids       Date:  2013-04-02       Impact factor: 1.880

Review 2.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

3.  The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study.

Authors:  G V Papamichail; T E Markatseli; A N Georgiadis; V G Xydis; H Milionis; A A Drosos; P V Voulgari
Journal:  Heart Vessels       Date:  2022-06-24       Impact factor: 1.814

Review 4.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

Review 5.  Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.

Authors:  Roberta Gualtierotti; Nicola Ughi; Giovanni Marfia; Francesca Ingegnoli
Journal:  Rheumatol Ther       Date:  2017-07-27

Review 6.  Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.

Authors:  Aikaterini Arida; Athanasios D Protogerou; George D Kitas; Petros P Sfikakis
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

7.  Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Authors:  Alexandre Virone; Jean-Philippe Bastard; Soraya Fellahi; Jacqueline Capeau; Stéphanie Rouanet; Jean Sibilia; Philippe Ravaud; Francis Berenbaum; Jacques-Eric Gottenberg; Jérémie Sellam
Journal:  RMD Open       Date:  2019-07-21

8.  Does a lack of physical activity explain the rheumatoid arthritis lipid profile?

Authors:  Hiba AbouAssi; Margery A Connelly; Lori A Bateman; K Noelle Tune; Janet L Huebner; Virginia B Kraus; Deborah A Winegar; James D Otvos; William E Kraus; Kim M Huffman
Journal:  Lipids Health Dis       Date:  2017-02-10       Impact factor: 3.876

Review 9.  Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate.

Authors:  Arduino A Mangoni; Sara Tommasi; Angelo Zinellu; Salvatore Sotgia; Ciriaco Carru; Matteo Piga; Gian Luca Erre
Journal:  Drugs Context       Date:  2018-11-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.